TDC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient buyer. TDC is sitting right on first support (28.54) with oversold readings that could spark a short bounce, but momentum is still bearish (MACD worsening) and there’s no near-term catalyst/news flow to force a reversal. Options positioning is bullish (call-heavy), yet without an Intellectia buy signal and with price still below key pivot (29.61), the higher-probability outcome is continued chop/down before a cleaner entry appears.
Trend/momentum is currently bearish-to-weak. MACD histogram is negative (-0.265) and expanding lower, which typically signals a downtrend still in control. RSI(6) at 24.6 is oversold (despite the provided label), implying downside may be getting exhausted and a dead-cat bounce is possible. Price (28.65 post-market) is hovering just above S1 (28.535); a break below raises risk toward S2 (27.874). To turn constructive quickly, TDC would need to reclaim the pivot (~29.605) and then push toward R1 (30.674).
Intellectia Proprietary Trading Signals:
Analyst tone has improved into late 2025/early 2026 (multiple target raises; one upgrade to Outperform with a $42 PT). Narrative tailwind: increasing focus on enterprise AI adoption and potential stabilization in enterprise spending (per RBC commentary). Profitability is improving (Q3 EPS and net income up strongly YoY). Upcoming earnings (2026-02-10 after hours) can act as a catalyst if guidance/ARR trends surprise positively. Options market is call-skewed (bullish positioning).
Price action/momentum remains weak (MACD negative and deteriorating), increasing the chance support breaks before a durable reversal. Revenue is still declining YoY, which keeps a lid on valuation expansion and can reintroduce "growth headwinds" concerns. No supportive news flow in the past week. Overhead resistance is close (pivot ~29.61 then ~30.67), so rebounds may stall quickly. Hedge funds/insiders show no meaningful recent accumulation trend, and there is no recent congress trading data indicating influential buying/selling.
Latest reported quarter: 2025/Q3. Revenue fell to $416M (-5.45% YoY), showing the top-line trend is still negative. However, profitability improved: net income rose to $40M (+25% YoY) and EPS to $0.42 (+27.27% YoY). Gross margin ticked up to 60.82% (+0.61 pts YoY), consistent with better efficiency/mix. Overall: improving margins/earnings, but growth is still the key gap (revenue contraction).
Recent analyst trend is improving but mixed. Over the last few months: (1) Citizens JMP upgraded to Outperform with a high $42 PT (bullish on FCF/share trajectory). (2) Morgan Stanley maintained Overweight and raised PT to $35. (3) RBC maintained Sector Perform and raised PT to $32 (constructive but not a clear buy). Offsetting this, Barclays kept Underweight (PT raised to $24) citing challenged growth outlook, and TD Cowen stayed Hold (PT $25). Wall Street pros: improving cash flow/margins and AI/enterprise spending tailwinds; cons: lingering revenue decline and uneven growth outlook, leaving consensus constructive but not universally confident.
